Background: TP53 mutations are the most common genetic alterations in human cancers. There are alsoseveral polymorphisms in both exons and introns of TP53 that may influence its anti-tumor functions and increasethe risk of cancer development. Associations of the TP53 intron 6 G13964C polymorphism with increased risk ofdevelopment of several cancers have been investigated in numerous studies, but the results were controversialand conflicting. In this study, we aimed to investigate the probable association of this polymorphism with riskof both thyroid and breast cancers among the Iranian-Azeri population. Materials and
Methods: We performedtwo separate case control studies on associations of the intron 6 polymorphism with two different kinds ofcancer. In one case-control study, a total of 75 patients with thyroid carcinoma and 180 controls were analyzedand the other study included 170 patients with breast cancer and 135 healthy women. The intron 6 genotypewas determined by RFLP-PCR and the SPSS 16 program was applied for data analysis.
Results: For thyroidcancer, the frequencies of GG genotype were 96.0% in patients and 93.3% in controls. The GC genotype had afrequency of 4.0 % in patients and 6.7% in controls. In the study on breast cancer, the frequency of GG and GCgenotypes in patients were 95.3% and 4.7%, respectively. In breast related control group, the frequency of GGgenotype was 93.3 % and the frequency of GC genotype was 6.7%. None of the cases and controls had the CCgenotype.
Conclusions: There was no significant association between the TP53 intron 6 G13964C polymorphismand risk of development of both thyroid and breast cancer in Iranian-Azeri patients.